HCA Healthcare Inc. (HCA)

NYSE: HCA · USD

$463

+13.36 (+3.0%)· Recorded snapshot

英語版にフォールバックJA

翻訳中のため英語版を表示しています

このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: HCA rated Hold

HCA Healthcare Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$504 / share

Potential value

$659 / share

Upside to FV

+9.8%

from $463

Moat

7/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$101.9B
Revenue (ttm)	78.7B
Net income (ttm)	6.8B
EPS (ttm)	$30.2
Shares out	216.5M
P/E (trailing)	15.3x
P/E (forward)	13.8x
Dividend	$3.12 (0.68%)
Volume	1,798,814
Beta	1.11

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 78.7B
Net income (ttm): 6.8B
EPS (ttm): $30.2
P/E (trailing): 15.3x
P/E (forward): 13.8x
Market cap: $101.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$58.75B	$60.23B	$64.97B	$70.60B	$75.60B	+6.5%
Gross profit	$22.49B	$23.18B	$25.58B	$28.68B	$31.37B	+8.7%
Operating income	$11.40B	$10.32B	$9.64B	$10.58B	$12.08B	+1.5%
Net income	$6.96B	$5.64B	$5.24B	$5.76B	$6.78B	-0.6%
EPS (diluted)	$21.16	$19.15	$18.97	$22.00	$28.33	+7.6%
EBITDA	$14.25B	$13.29B	$12.72B	$13.90B	$15.60B	+2.3%
R&D	—	—	—	—	—	—
SG&A	$26.78B	$27.69B	$29.49B	$31.17B	$8.00B	-26.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	売り
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	売り
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	強い買い
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	売り
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	縮小
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	縮小

Base and Bull scenarios

Base60%

Price target

$504.46

+9.8% from spot

The modal path reflects steady same-facility equivalent admission expansion supported by favorable Sunbelt demographic trends, tempered by gradual outpatient procedure migration. Operating margins remain stable as purchasing efficiencies through the group purchasing organization balance clinical wage pressures, while regular share repurchases funded by operational cash conversion drive compound per-share growth.

Steady same-facility admission growth matching long-term demographic trends
Operating margins remaining durable near historical normalized levels
Continued annual share repurchases funded by operating cash generation

Bull20%

Price target

$658.79

+43.4% from spot

Under the upside trajectory, rapid demographic expansion in key Sunbelt metropolitan markets drives accelerated commercial admissions and a rebound in higher-acuity inpatient surgical procedures. Centralized purchasing scale and clinical workflow productivity contain operating expense inflation, expanding operating margins and enabling robust free cash flow to accelerate share repurchase execution.

Accelerated inpatient surgical admission growth and commercial payer rate enhancements
Operating margins expanding toward peak historical levels through clinical labor productivity
Sustained free cash flow generation driving accelerated share count retirement

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($504.46). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
8.3%	$557	$578	$602	$629	$660
8.8%	$513	$530	$548	$569	$592
9.3%	$476	$490	$504	$521	$539
9.8%	$445	$456	$468	$482	$496
10.3%	$419	$428	$438	$449	$461

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.9

P25 n/aP50 n/aP75 n/a

Trailing P/E15.6

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC21.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All HCA indicators

Market & fundamental data

Available fields

276

Groups with data

Currency

USD

Showing 276 of 276 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000860730
Company name	HCA Healthcare, Inc.
Country	United States
Country code	US
CUSIP number	40412C101
Earnings date	2026-10-27
Earnings time	bmo
Employees	320,000
Employees change	4,000
Employees growth	1.27%
Enterprise value	$151.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-09-30
First seen	2026-05-09
Fiscal year end	December
Founded	1968
In index	SP500
Industry	Medical Care Facilities
Is primary listing	Yes
Is SPAC	No
ISIN number	US40412C1018
Last 10-K release date	2026-02-10
Last earnings date	2026-10-27
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$100.3B
Market cap category	Large-Cap
Next earnings date	2027-01-26
Options	Yes
Price	$463.33
Price currency	USD
Sector	Healthcare
SIC code	8062
Stock price date	2026-10-28
Symbol	HCA
U.S. state	Tennessee
Website	https://www.hcahealthcare.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	15.46x
Average P/E ratio (10Y)	12.9x
Average P/E ratio (3Y)	14.91x
Average P/E ratio (5Y)	13.5x
Earnings yield	6.52%
EV/Earnings	22.27x
EV/EBIT	12.52x
EV/EBITDA	9.56x
EV/FCF	25.27x
EV/Sales	1.92x
FCF / EV yield	3.96%
FCF yield	6.01%
Forward EV/Sales	1.87x
Forward P/E	14.93x
Forward P/S	1.23x
Industry forward P/E	14.95x
Industry P/E	18.37x
Lynch fair value	$151.12
Lynch upside	-67.09%
P/(FCF - SBC) ratio	17.85x
P/(OCF - SBC) ratio	9.24x
P/E ratio	15.33x
P/FCF ratio	16.64x
P/OCF ratio	8.9x
P/S ratio	1.26x
PEG ratio	1.58x
Price/EBITDA ratio	6.3x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.31%
EBITDA margin	20.06%
Effective tax rate	20.6%
FCF margin	7.59%
Gross margin	42.76%
Operating margin	15.31%
Pretax margin	12.48%
Profit margin	8.61%
Profit per employee	$21,175
Profitable quarters	66
Profitable years	18
Revenue per employee	$245,941
ROA	12.23%
ROA (5Y)	11.64%
ROCE	27.6%
ROIC	21.36%
ROIC (5Y)	19.69%
SBC / revenue	0.51%
Tax / revenue	2.57%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	17.06%
EPS growth (Q)	4.45%
EPS growth (QoQ)	-4.6%
EPS growth 10Y	16.95%
EPS growth 3Y	13.98%
EPS growth 5Y	9.12%
EPS growth quarters	6
EPS growth years	2
FCF growth	-26.22%
FCF growth (Q)	-0.77%
FCF growth (QoQ)	181.16%
FCF growth 3Y	10.93%
Gross profit growth	9.35%
Gross profit growth (Q)	5.38%
Gross profit growth 3Y	11.24%
Gross profit growth 5Y	8.44%
Net income growth	6.81%
Net income growth (Q)	-3.9%
Net income growth (QoQ)	-7.06%
Net income growth 3Y	5.83%
Net income growth 5Y	0.63%
Net income growth quarters	6
Net income growth years	2
OCF growth	-12.99%
OCF growth (Q)	1.02%
OCF growth (QoQ)	91.05%
OCF growth 10Y	7.32%
OCF growth 3Y	6.36%
OCF growth 5Y	30.66%
Operating income growth	3.6%
Operating income growth (Q)	-0.71%
Operating income growth 3Y	9.26%
Operating income growth 5Y	4.35%
Revenue growth	5.82%
Revenue growth (Q)	3.59%
Revenue growth (QoQ)	-1.88%
Revenue growth 10Y	6.71%
Revenue growth 3Y	7.61%
Revenue growth 5Y	6.3%
Revenue growth quarters	15
Revenue growth years	16

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-5.2B
Depreciation and amortization	$3.7B
EBIT	$12.1B
EBITDA	$15.8B
EPS	$30.22
FCF per share	$27.59
Financing cash flow	$-5.2B
Free cash flow	$6B
Free cash flow minus SBC	$5.6B
Gross profit	$33.6B
Income taxes	$2B
Investing cash flow	$-6.1B
Net borrowing	$5.8B
Net cash flow	$-89M
Net income	$6.8B
Operating cash flow minus SBC	$10.8B
Operating income	$12.1B
Revenue	$78.7B
Stock-based compensation	$404M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-37.18
Debt / EBITDA	3.12
Debt / FCF	8.78
Interest coverage	5.1
Long-term assets	$47.2B
Long-term liabilities	$48.3B
Net cash (debt)	$-51.5B
Net cash / market cap	-51.82%
Net debt / EBITDA	3.26
Net debt / FCF	8.63
Piotroski F-Score	6
Property, plant and equipment	$34.5B
Shareholders' equity	$-4.6B
Tangible book value	$-19.3B
Tangible book value per share	$-88.74
Total assets	$63.5B
Total cash	$908M
Total debt	$52.4B
Total liabilities	$68.1B
WACC	8.02%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.28
Current assets	$16.2B
Current liabilities	$19.8B
Current ratio	0.82
Inventory turnover	26.47
Net working capital	$3.6B
Quick ratio	0.63
Working capital	$-3.6B
Working capital turnover	-25.51

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	8.7%
Dividend growth	8.33%
Dividend growth (3Y)	9.14%
Dividend growth (5Y)	10.2%
Dividend growth years	5
Dividend payment date	2026-12-29
Dividend payment years	9
Dividend payout frequency	Quarterly
Dividend per share	$3.12
Dividend yield	0.68%
Ex-dividend date	2026-12-15
FCF payout ratio	11.31%
Last dividend	$0.78
Payout ratio	10.32%
Shareholder yield	9.37%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	480.14%
10Y return CAGR	20.14%
10Y total return	526.07%
150-day SMA	$422.64
15Y price change	1,941.3%
15Y return CAGR	24.72%
15Y total return	2,648.74%
1D price change	2.97%
1M price change	5.62%
1M total return	5.62%
1W price change	-1.21%
1W total return	-1.21%
1Y price change	-1.66%
1Y return CAGR	-0.98%
1Y total return	-0.98%
20-day SMA	$453.07
200-day SMA	$444.41
3M price change	18.09%
3M total return	18.31%
3Y price change	104.23%
3Y return CAGR	27.84%
3Y total return	108.95%
50-day SMA	$434.59
50-day SMA vs 200-day SMA	50under200
52-week high	$556.52
52-week high date	2026-03-12
52-week low	$353.99
52-week low date	2026-07-14
5Y price change	87.52%
5Y return CAGR	14.36%
5Y total return	95.54%
6M price change	3.22%
6M total return	3.61%
All-time high	$556.52
All-time high date	2026-03-12
All-time low	$17.03
All-time low date	2011-08-09
Average true range (ATR)	$14.89
Average volume	1.2M
Beta (1Y)	0.25
Beta (2Y)	0.29
Beta (5Y)	1.11
Change from 52-week high	-16.75%
Change from 52-week low	30.89%
Change from all-time high	-17.32%
Change from all-time low	2,601.76%
Change from open	3.65%
Day's gap	-0.66%
Dollar volume	$833.4M
High price	$465.91
Low price	$447.00
Monthly RSI	58.08
Open price	$447.00
Position in 52-week range	86.36%
Premarket change	-0.66%
Premarket close	$449.96
Premarket price	$447.00
Premarket volume	418
Previous close	$449.96
Price vs 150-day SMA	8.87%
Price vs 20-day SMA	1.55%
Price vs 200-day SMA	3.53%
Price vs 50-day SMA	5.87%
Relative volume	1.46
RSI	56.28
Sharpe ratio	-0.01
Sharpe ratio (3Y)	0.8
Sharpe ratio (5Y)	0.45
Sortino ratio	0.18
Sortino ratio (3Y)	1.34
Sortino ratio (5Y)	0.8
Volume	1.8M
Weekly RSI	57.49
YTD price change	-1.45%
YTD total return	-0.92%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	144.3M
Float percentage	66.66%
Shares change (QoQ)	-2.52%
Shares change (YoY)	-8.7%
Shares held by insiders	1.43%
Shares held by institutions	62.07%
Shares outstanding	216.5M
Short % of float	3.38%
Short % of shares	2.26%
Short ratio	3.2 days

Deeper analysis on HCA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this HCA report

What is the latest published HCA stock rating?

HCA Healthcare Inc. is shown with Hold in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HCA analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/HCA/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for HCA?

The latest published report analyzed 2026-10-22 gives HCA a fair value of USD 504 and a potential value of USD 659. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the HCA page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldHCA · Fair value $504+9.8%

Read full analysis →

HCA Healthcare Inc. (HCA)

Our latest published analysis: HCA rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · HCA

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All HCA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on HCA

Frequently asked questions

レーティング履歴

Category	Score	Reading
Valuation	6.0
Management	8.5
Balance Sheet	3.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	4.5
Competitive Moat	7.0
Earnings Quality	8.0
Capital Efficiency	7.5